The safety and efficacy of Uptravi in children aged 0 to less than 18 years have not yet been
established. No data are available. Administration of selexipag in the paediatric population is not
recommended. Animal studies indicated an increased risk of intussusception, but the clinical relevance
of these findings is unknown (see section 5.3).